Dr Reid is a respiratory physician determining the relationships between bacterial pathogen behaviour and the host immune response in Cystic Fibrosis. The aim of his research is to use observations made in the clinical setting to develop novel therapeutics and identification of biomarkers that will be employed to pre-empt and better treat clinical disease with the ultimate aim of improving length and quality of life.
Evolution Of Airway Function And Inflammation In Early Cystic Fibrosis Lung Disease
Funder
National Health and Medical Research Council
Funding Amount
$494,447.00
Summary
Our goal is to evaluate if lung function can identify the onset of early lung disease in infants with cystic fibrosis (CF). We aim to evaluate: - Changes in lung function in infants with CF. - Associations between lung function and lung inflammation and infection. - Links between infant lung function and disease severity at 2 years of age. The long term aims are to determine how useful lung function will be in trials of novel treatments for the early treatment of CF.
Early Life Exposures And Chronic Disease: Mechanisms And Preventative Strategies
Funder
National Health and Medical Research Council
Funding Amount
$851,980.00
Summary
The world is facing an epidemic of chronic disease and adverse environmental exposures in early life are partly responsible. One reason why we have not been able to do more to prevent this is the lack of appropriate methods for measuring environmental exposures during pregnancy and infancy. My research will develop and validate methods for measuring exposures early life and the health consequences of these exposures with the aim of developing preventative interventions
The Importance Of Neutrophil Plasticity In Early Cystic Fibrosis Lung Disease
Funder
National Health and Medical Research Council
Funding Amount
$318,768.00
Summary
Lung disease is a lifelong problem for people with cystic fibrosis (CF). Blood immune cells called neutrophils swarm the lung and cause ongoing damage. No treatments exist because how CF lungs talk to neutrophils is poorly understood. I will apply new skills from an international neutrophil expert to study samples from AREST CF, a world leading CF research group. This unique combination will recreate the early CF lung in the laboratory, testing triggers of CF lung disease and potential drugs.
The Emerging Problem Of Non-tuberculous Mycobacteria Infection: Understanding Aetiology, Geospatial Epidemiology And Developing Interventions
Funder
National Health and Medical Research Council
Funding Amount
$988,791.00
Summary
This project will be largest study of non-tuberculous mycobacterial (NTM) infection in cystic fibrosis. By combining growing the bacteria with detailed information from the CF patient data registry, geographical location and environmental conditions, this study will provide novel insights into factors associated with NTM. Gene sequencing and airway infection profiling will extend understanding and has the potential to identify novel risk factors and biomarkers for NTM-related airways disease.
Revolutionising The Diagnosis And Monitoring Of CF Lung Disease
Funder
National Health and Medical Research Council
Funding Amount
$818,391.00
Summary
Cystic fibrosis (CF) lung disease starts early in childhood and relentlessly progresses, with early death a common outcome. There is currently no method capable of detecting very early disease onset nor directly assessing the effectiveness of putative treatments. This project will apply our globally unique X-ray imaging tools, which are capable of imaging lung function at any point across the entire lung, for the very early detection of CF and assessment of clinically applicable treatments.